EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Debulking Hepatectomy for Colorectal Liver Metastasis Conveys Survival Benefit

Jennifer A Kalil iD, Lucyna Krzywon, Oran Zlotnik iD, Hugo Perrier, Stephanie K Petrillo, Prosanto Chaudhury iD, Erik Schadde, Peter Metrakos

Cancers · 29.04.2024 · 16 (9) · 1730

DOI: 10.3390/cancers16091730 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancers, online erschienen am 29.04.2024. Verfasst von Jennifer A Kalil und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgery, Royal Victoria Hospital-McGill University Health Center, 1001 Blvd Décarie, Montréal, QC H4A 3J1, Canada. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

(1)

Background

Despite advances in surgical technique and systemic chemotherapy, some patients with multifocal, bilobar colorectal liver metastases (CRLM) remain unresectable. These patients may benefit from surgical debulking of liver tumors in combination with chemotherapy compared to chemotherapy alone. (2)

Methods

A retrospective study including patients evaluated for curative intent resection of CRLM was performed. Patients were divided into three groups: those who underwent liver resection with recurrence within 6 months (subtotal debulked, SD), those who had the first stage only of a two-stage hepatectomy (partially debulked, PD), and those never debulked (ND). Kaplan–Meier survival curves and log-rank test were performed to assess the median survival of each group. (3)

Results

174 patients underwent liver resection, and 34 patients recurred within 6 months. Of the patients planned for two-stage hepatectomy, 35 underwent the first stage only. Thirty-two patients were never resected. Median survival of the SD, PD, and ND groups was 31 months, 31 months, and 19.5 months, respectively (p = 0.012); (4)

Conclusions

Patients who underwent a debulking of CRLM demonstrated a survival benefit compared to patients who did not undergo any surgical resection. This study provides support for the evaluation of intentional debulking versus palliative chemotherapy alone in a randomized trial.

Schlagwörter

Stichwörter der Autor:innen

chemotherapycolorectal liver metastasesdebulking hepatectomyliver resectionmedian survival

Autor:innen und Institutionen

  • Department of Surgery, Royal Victoria Hospital-McGill University Health Center, 1001 Blvd Décarie, Montréal, QC H4A 3J1, Canada.
  • Cancer Research Program, Research Institute-McGill University Health Center, 1001 Blvd Décarie, Montréal, QC H4A 3J1, Canada.
  • Hepatobiliary and Pancreatic Surgery, Surgical Center in Zurich, Surgery Center St. Anna in Lucerne, Beausite Hospital in Berne, Hirslanden Corporation, Witteliker Str. 40, 8032 Zurich, Switzerland.
  • Department of Surgery, Rush University Medical Center, 653 W Congress Pkwy 12, Chicago, IL 60612, USA.

ORCID-Profile: Jennifer A Kalil, Oran Zlotnik, Prosanto Chaudhury

Zitieren

APA

Kalil, J. A., Krzywon, L., Zlotnik, O., Perrier, H., Petrillo, S. K., Chaudhury, P., Schadde, E., & Metrakos, P. (2024). Debulking Hepatectomy for Colorectal Liver Metastasis Conveys Survival Benefit. Cancers, 16(9), 1730. https://doi.org/10.3390/cancers16091730

Vancouver

Kalil JA, Krzywon L, Zlotnik O, Perrier H, Petrillo SK, Chaudhury P, et al. Debulking Hepatectomy for Colorectal Liver Metastasis Conveys Survival Benefit. Cancers. 2024;16(9):1730. doi:10.3390/cancers16091730

BibTeX
@article{Kalil2024,
  author = {Kalil, Jennifer A and Krzywon, Lucyna and Zlotnik, Oran and Perrier, Hugo and Petrillo, Stephanie K and Chaudhury, Prosanto and Schadde, Erik and Metrakos, Peter},
  title = {Debulking Hepatectomy for Colorectal Liver Metastasis Conveys Survival Benefit},
  journal = {Cancers},
  year = {2024},
  volume = {16},
  number = {9},
  pages = {1730},
  doi = {10.3390/cancers16091730}
}
Kostenlos starten →